Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
INVO FertilityIVF -3.72%35 EBITDA Margin % is 58.30% as of Jun. 2026. GuruFocus rates IVF with a GF Score™ of 35/100 and a GF Value™ of $4.69 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 814 Medical Devices & Instruments companies, INVO Fertility ranks worse than 78.26% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. INVO Fertility's EBITDA for the
three
months ended in Jun. 2026 was $1.27 Mil. INVO Fertility's Revenue for the
three
months ended in Jun. 2026 was $2.18 Mil. Therefore, INVO Fertility's EBITDA margin for the quarter that ended in Jun. 2026 was 58.30%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
INVO Fertility EBITDA Margin % Related Terms
INVO Fertility EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for INVO Fertility's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IVF vs AMIX, AEMD, NUMD: EBITDA Margin % Comparison
For the Medical Devices subindustry, INVO Fertility's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
INVO Fertility EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, INVO Fertility's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where INVO Fertility's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INVO Fertility (IVF) has a EBITDA Margin % of 58.30% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on INVO Fertility and its competitors. According to the industry distribution chart, INVO Fertility ranks #637 out of 814 companies in the Medical Devices & Instruments industry, placing it in the top 78.3%.
Is INVO Fertility's EBITDA Margin % too high?
INVO Fertility's current EBITDA Margin % is 58.30%. The Medical Devices & Instruments industry median EBITDA Margin % is 8.07. INVO Fertility's value of 58.30% is 622.9% above this industry median. Based on the distribution chart, INVO Fertility ranks #637 out of 814 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, INVO Fertility has a GF Score™ of 35/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does INVO Fertility's EBITDA Margin % compare to AMIX and AEMD?
According to the Medical Devices & Instruments industry distribution chart, INVO Fertility ranks #637 out of 814 companies for EBITDA Margin %. This places INVO Fertility in the lower half of its industry. The industry median EBITDA Margin % is 8.07. INVO Fertility's value of 58.30% is 622.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 8.07, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. INVO Fertility's current EBITDA Margin % of 58.30% is 622.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on INVO Fertility and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 8.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. INVO Fertility's current EBITDA Margin % is 58.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is INVO Fertility stock overvalued right now?
Based on GuruFocus' analysis, INVO Fertility (IVF) is currently considered Possible Value Trap. The stock's GF Value™ is $4.69, compared to a current price of $1.06 — trading 77.4% below its estimated fair value. The current EBITDA Margin % is 58.30% and 622.9% above the Medical Devices & Instruments industry median of 8.07. INVO Fertility's overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For INVO Fertility (IVF), the current EBITDA Margin % is 58.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is INVO Fertility (IVF) Overvalued in 2026?
Based on GuruFocus' analysis, INVO Fertility stock appears to be undervalued.
The current stock price of $1.06 is trading 77.4% below its estimated GF Value™ of $4.69.
GuruFocus considers INVO Fertility to be Possible Value Trap.
Key valuation signals for IVF:
EBITDA Margin %: 58.30%
GF Value™: $4.69 vs. price of $1.06 (77.4% below fair value)
Industry Position: 622.9% above the Medical Devices & Instruments median (#637 of 814)
No single metric tells the full story. See the IVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
INVO Fertility Inc is a healthcare services fertility company dedicated to expanding assisted reproductive technology (ART) care to patients in need. It is offering the intravaginal culture (IVC) procedure enabled by INVOcell medical device (INVOcell). The INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman's body. The company's segments include: The Clinics Services operating segment consisting of financial information for WFI and the Atlanta Clinic and The INVOcell Device operating segment consisting of financial information relating to the manufacture and sales of the INVOcell.
35GF Score
Get the complete analysis for IVF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IVF has been successfully added to your 
